Topic

North Carolina

A collection of 444 issues

Renewing Opsumit (Macitentan) Approval with UnitedHealthcare in North Carolina: 2025 Requirements & Timeline

Answer Box: Opsumit (macitentan) renewal with UnitedHealthcare in North Carolina requires submitting updated clinical documentation 30-60 days before your current authorization expires. Key 2025 changes: OptumRx is eliminating many chronic disease reauthorizations, but Opsumit's status must be verified through your provider portal. If still required, submit WHO functional
6 min read

How to Get Galafold (migalastat) Covered by UnitedHealthcare in North Carolina: Requirements, Appeals, and Smart NC External Review

Answer Box: Getting Galafold Covered by UnitedHealthcare in North Carolina To get Galafold (migalastat) covered by UnitedHealthcare in North Carolina, you need: (1) confirmed Fabry disease diagnosis with amenable GLA variant documented by genetic testing, (2) specialist evaluation (nephrology, genetics, or metabolics), and (3) prior authorization submission through OptumRx with
5 min read

Coding That Helps Get Rystiggo (Rozanolixizumab-noli) Approved by UnitedHealthcare in North Carolina: ICD-10, J-Code, and Prior Authorization Guide

Answer Box: Fast Track to Rystiggo Coverage Getting Rystiggo (rozanolixizumab-noli) covered by UnitedHealthcare in North Carolina requires proper coding and prior authorization. Use ICD-10 codes G70.00 (no exacerbation) or G70.01 (with exacerbation), bill with J-code J9333, and document AChR or MuSK antibody positivity. UnitedHealthcare requires prior authorization through
5 min read

How to Get Enhertu (fam-trastuzumab deruxtecan-nxki) Covered by Blue Cross Blue Shield of North Carolina: Complete Forms, Appeals & Timelines Guide

Answer Box: Getting Enhertu Covered in North Carolina Blue Cross Blue Shield of North Carolina requires prior authorization for Enhertu (fam-trastuzumab deruxtecan-nxki) as of July 2024. Your fastest path to approval: (1) Ensure your provider submits complete HER2 testing documentation and clinical notes via the Blue Cross NC provider portal,
5 min read

If Zolgensma Isn't Approved by Blue Cross Blue Shield in North Carolina: Spinraza, Evrysdi & Exception Strategies

Answer Box: Your Next Steps When Zolgensma Is Denied If Blue Cross Blue Shield North Carolina denies Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy, you have proven alternatives: Spinraza (nusinersen) and Evrysdi (risdiplam) are both FDA-approved, disease-modifying SMA treatments typically covered on BCBS formularies. First step: Request your neurologist submit
6 min read

How to Get Cimzia (Certolizumab Pegol) Covered by Blue Cross Blue Shield of North Carolina: Complete Guide to Prior Authorization, Appeals, and State Protections

Answer Box: Getting Cimzia Covered in North Carolina Cimzia (certolizumab pegol) requires prior authorization from Blue Cross Blue Shield of North Carolina and is subject to step therapy requirements. The fastest path to approval: 1) Submit PA with documented failure of preferred TNF inhibitors, 2) Include TB/HBV screening and
5 min read